Chalmers James D, Singanayagam Aran, Scally Caroline, Hill Adam T
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Ann Emerg Med. 2009 May;53(5):633-8. doi: 10.1016/j.annemergmed.2008.12.022. Epub 2009 Feb 7.
Severity assessment is an important component of the management of community-acquired pneumonia. Clinicians are increasingly searching for biomarkers to aid in clinical decisions. Coagulation disorders can accompany severe pneumonia. We seek to investigate the association of D-dimer, a fibrinolysis biomarker, and 30-day mortality or the need for mechanical ventilation or vasopressor support in emergency department (ED) patients with community-acquired pneumonia.
We prospectively enrolled ED patients with community-acquired pneumonia between December 2005 and January 2008 in a convenience manner. We measured D-dimer level with the Vitek ImmunoDiagnostic Assay System. To assess clinical illness severity, both CURB65 and the Pneumonia Severity Index (Pneumonia Severity Index class) were calculated. Our primary outcomes were 30-day mortality and need for mechanical ventilation or vasopressor support.
Of the 314 enrolled patients, 23.9% of patients had a D-dimer level less than 500 ng/mL on initial ED measurement, and 81.3% of these patients were in Pneumonia Severity Index class I to III. A D-dimer level of less than 500 ng/mL had a negative likelihood ratio of 0 (95% confidence interval 0 to 1.37) for 30-day mortality and 0.33 (95% confidence interval 0.09 to 1.27) for need for mechanical ventilation or vasopressor support. For 30-day mortality, the area under the receiver operator characteristic curve for D-dimer was similar to both CURB65 and Pneumonia Severity Index class. For mechanical ventilation or vasopressor support, the area under the receiver operator characteristic curve for D-dimer was lower than that for CURB65 but did not differ from that for Pneumonia Severity Index.
An admission D-dimer level less than 500 ng/mL is associated with low risk of short-term death and major morbidity in patients with community-acquired pneumonia.
严重程度评估是社区获得性肺炎管理的重要组成部分。临床医生越来越多地寻找生物标志物以辅助临床决策。凝血功能障碍可能伴随严重肺炎。我们旨在研究纤溶生物标志物D - 二聚体与急诊科(ED)社区获得性肺炎患者30天死亡率或机械通气或血管活性药物支持需求之间的关联。
我们于2005年12月至2008年1月以方便抽样的方式前瞻性纳入了ED社区获得性肺炎患者。我们使用Vitek免疫诊断分析系统测量D - 二聚体水平。为评估临床疾病严重程度,计算了CURB65和肺炎严重指数(肺炎严重指数分级)。我们的主要结局是30天死亡率以及机械通气或血管活性药物支持需求。
在314名纳入患者中,23.9%的患者在ED初始测量时D - 二聚体水平低于500 ng/mL,其中81.3%的患者属于肺炎严重指数I至III级。D - 二聚体水平低于500 ng/mL对于30天死亡率的阴性似然比为0(95%置信区间0至1.37),对于机械通气或血管活性药物支持需求的阴性似然比为0.33(95%置信区间0.09至1.27)。对于30天死亡率,D - 二聚体的受试者工作特征曲线下面积与CURB65和肺炎严重指数分级相似。对于机械通气或血管活性药物支持,D - 二聚体的受试者工作特征曲线下面积低于CURB65,但与肺炎严重指数分级无差异。
入院时D - 二聚体水平低于500 ng/mL与社区获得性肺炎患者短期死亡和主要并发症的低风险相关。